时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
（原文未给出可直接抽取的对应表述）
方法
Despite metformin being the first-line therapy, many patients require combination treatment due to the progressive and multifactorial nature of T2DM.；This study has evaluated efficacy and safety of FDC of dapagliflozin (DAPA), glimepiride (GLIM), and metformin (MET) immediate release (IR) tablet versus co-administration of GLIM and MET tablets in patients with T2DM.；Methods: This phase 3, randomized, open-label study included 536 Indian patients with T2DM [glycated hemoglobin (HbA1c) ≥ 8.0% and P.
核心结论
Conclusions: The FDC of DAPA + GLIM + MET IR tablet demonstrated superior glycemic control over co-administration of glimepiride and metformin and acceptable safety profile, making it an effective therapeutic option for T2DM management.；The FDC demonstrated significantly greater HbA1c reduction and a higher proportion of patients achieving target glycemic control, with comparable tolerability to co-administered therapy.；These findings support the use of FDC as an effective therapeutic option for T2DM, potentially simplifying treatment regimens and improving patient outcomes in clinical practice.
局限
However, adherence declines as the number of medications increases [33, 34].
对本项目的价值
中等价值：属「代谢 / 内分泌 / 肝肾老化」方向；代谢 / 内分泌 / 肝肾老化的界面栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.6/5（★★★☆☆）
全文来源
出版商/仓储 OA PDF（正文 17,328 字符，题名指纹 1.0，正文内 DOI 命中，已过题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：达格列净、格列美脲与二甲双胍固定剂量复方片治疗 2 型糖尿病的疗效与安全性：III 期试验
- 英文标题：Efficacy and Safety of Dapagliflozin, Glimepiride, and Metformin Fixed-Dose Combination Tablet in Type 2 Diabetes: A Phase III Trial.
- 期刊与标识：Advances in therapy · PMID 42970163 · DOI 10.1007/s12325-026-03791-1